Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Radiological Techniques and Scans
  •  Brain and Spinal Cord Cancer
  •  Radiation Oncology
  •  Neoadjuvant Therapy
  •  Colorectal Cancer
  •  Thoracic Oncology
  •  Targeted Therapy
  •  General Oncology

Abstract

Citation: Clin Oncol. 2017;2(1):1233.DOI: 10.25107/2474-1663.1233

Recent Molecular Immunological Chemotherapy for Gastrointestinal Malignancies

Masaya Mukai, Takayuki Tajima, Sayuri Hasegawa, Daiki Yokoyama, Takuya Koike, Shinichirou Hiraiwa, Tomoko Sugiyama and Takuma Tajiri

Department of Digestive Surgery, Tokai University Hachioji Hospital, Japan
Departmentof Digestive Surgery, Tokai University Oiso Hospital, Japan
Department of Pathology, Tokai University Hachioji Hospital, Japan

*Correspondance to: Masaya Mukai 

 PDF  Full Text Commentary | Open Access

Abstract:

Efficacy of anticancer agents is generally dose-dependent and thus is determined by the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLT). Based on new theories such as the role of immune checkpoints in tumor cell survival, it seems important to investigate the optimum dosing method for antibody-drug conjugates that can have multimodal pharmacological actions, rather than inducing bone marrow suppression/immunosuppression at the MTD/DLT like traditional chemotherapy, allowing the cytotoxic anticancer agent to be administered at the Minimally Effective Cytotoxic Dose (MECD) that maintains host antitumor immunity together with cytotoxic activity. At present, both molecular-targeting agents and immune checkpoint inhibitors are available. As a future treatment strategy, we need to develop regimens that do not cause bone marrow suppression and do not require suspension or discontinuation of treatment due to toxicities. With such new regimens, cancer cells will be killed effectively while adverse reactions are reduced, so patients can enjoy improved high quality of life and longer progression-free survival. It is strongly anticipated that molecular-targeting therapy will be developed for gastrointestinal cancer, which will allow the total dose to be given safely at optimal schedules.

Keywords:

Molecular-targeting therapy; Minimally effective cytotoxic dose (MECD); Maximum tolerated dose (MTD); Dose-limiting toxicities (DLT); Immunosuppression

Cite the Article:

Mukai M, Tajima T, Hasegawa S, Yokoyama D, Koike T, Hiraiwa S, et al. Recent Molecular Immunological Chemotherapy for Gastrointestinal Malignancies. Clin Oncol. 2017; 2: 1233.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Pediatric Cancer Predisposition Documentation Tool - Standardized Reporting Form for Children and Adolescents with Suspected Cancer Predisposition Syndrome
 Abstract  PDF  Full Text
Research on the Role of Ezrin Gene in the Pathological Process of Cervical Cancer
 Abstract  PDF  Full Text
View More...